drugset / Trial / NCT07388277
CC-97540 in Patients With Antineutrophil Cytoplasmic Antibody-associated Vasculitis
Phase 1/2
Active not recruiting
12 enrolled
Massachusetts General Hospital
Bristol-Myers Squibb · collab
NaSingle-groupOpen-labelTreatment
Summary
The purpose of this study is to evaluate the safety of CC-97540 in relapsed or refractory severe antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis.
Timeline
- Start
- 2026-03-30
- Primary completion
- 2028-12-31
- Completion
- 2029-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Zolacabtagene- Autoleucel | Cell therapy | — | Intravenous |
| Background | Cyclophosphamide | Other / unclassified | — | Intravenous |
| Background | Fludarabine | Small molecule | — | Intravenous |